Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) EBT (2021 - 2026)

Nuvectis Pharma has reported EBT over the past 6 years, most recently at -$6.0 million for Q1 2026.

  • Quarterly results put EBT at -$6.0 million for Q1 2026, down 13.47% from a year ago — trailing twelve months through Mar 2026 was -$27.2 million (down 34.72% YoY), and the annual figure for FY2025 was -$26.4 million, down 39.17%.
  • EBT reached -$6.0 million in Q1 2026 per NVCT's latest filing, up from -$7.3 million in the prior quarter.
  • Across five years, EBT topped out at -$2.9 million in Q1 2022 and bottomed at -$7.5 million in Q3 2025.
  • Median EBT over the past 5 years was -$5.9 million (2022), compared with a mean of -$5.5 million.
  • Peak annual rise in EBT hit 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
  • Over 5 years, EBT stood at -$6.7 million in 2022, then grew by 1.11% to -$6.6 million in 2023, then grew by 5.65% to -$6.2 million in 2024, then decreased by 17.06% to -$7.3 million in 2025, then increased by 17.28% to -$6.0 million in 2026.
  • Business Quant data shows EBT for NVCT at -$6.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$7.5 million in Q3 2025.